UbiQ
targeting the ubiquitin system

LRRASLG–GG-H2B(113-125) *(human sequence, synthetic)*

UbiQ code	:	UbiQ-333
Batch #	:	B01065022-001
Amount	:	50 ug, lyophilized powder
Purity	:	≥95% by RP-HPLC
Mol. Weight	:	2.26 kDa
Storage	:	upon arrival, powder at –20°C, solution at –80°C. Please avoid multiple freeze/thaw cycles.

Productsheet

Background. UbiQ-333 is based on an H2B(113-125) peptide which is modified on the N-terminus with a PKA (cAMP-dependent Protein Kinase) sequence: LRRASLG; a Gly-Gly linker is used to create extra space between the PKA and H2B peptide sequence. It can be used as a control reagent for UbiQ-332.

sequence

LRRASLGGGEGTKAVTKYTSSK



Figure 1. LC-MS analysis. Mobile phase A= 1% CH_3CN, 0.1% formic acid in milliQ and B= 1% milliQ and 0.1% formic acid in CH_3CN. XBridge BEH300 C18 3.5 µm 4.6x100mm; column T= 40°C, flow= 0.8 mL/min. Gradient: 30–80%B over 3.5 min.

important: sample preparation

- dissolve the powder in as little DMSO as possible, e.g. 4.5 – 9 mg/mL (2.00 – 4.00 mM)
- add this DMSO stock slowly to milliQ (please note the order of addition)
- buffer the aq. solution as desired

UbiQ Bio BV
Chamber of Commerce 50023438
VAT NL822502136B01

Science Park 408
1098 XH Amsterdam
The Netherlands

t +31 20 303 1970
e info@ubiqbio.com
i www.ubiqbio.com

Rabobank
IBAN NL86RABO0150658907
BIC/SWIFT RABONL2U